Form 4: Biogen Director William Hawkins Receives Stock Grant

Biogen Inc. director William A. Hawkins was granted 1,505 restricted stock units as part of his director compensation.

Summary

• Director William A. Hawkins acquired 1,505 shares of Biogen Inc. common stock.
• The acquisition was in the form of restricted stock units (RSUs) granted at a price of $0.
• Following this transaction, the director's total beneficial ownership is 10,365 shares.
• The RSUs are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Director alignment with shareholder interests through increased equity ownership.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock units will vest on the earlier of the next annual meeting or June 9, 2027.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure board members maintain a vested interest in long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for large-cap pharmaceutical companies like Amgen, Gilead, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the 1,505 restricted stock units on the earlier of the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Insider Trading, Form 4, Director Compensation, Equity Grant